Disseminated Enteroviral Infection Associated with Obinutuzumab

Abstract

Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.

Keywords

• obinutuzumab
• CD 20 monoclonal antibody
• enterovirus
• dermatomyositis
• rituximab
• viruses